Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Target for Treating the Aggressive Brain Tumor Gliobastoma: Telomere Proteins!

A New Target for Treating the Aggressive Brain Tumor Gliobastoma: Telomere Proteins!
In this article

Glioblastoma (GBM) is a brain cancer that is very difficult to treat. The inability of medicines to cross the blood-brain barrier effectively and the diverse genetic and biological mechanisms of brain tumors worsen the disease course. In November 2017, Cançer Cell published a study reporting the discovery of an effective method to inhibit glioblastoma cell growth.

The main molecular targets in the study were telomere-associated proteins. As is known, telomerase activity is very high in cancer cells. This allows them to maintain their telomeres at a certain level, giving them unlimited proliferative capacity. Researchers investigated whether blocking telomere proteins would be effective in glioblastoma, which has different biology.

Glioblastomaarises from star-shaped nervous system cells called astrocytes. These tumors usually contain glioblastoma stem cells, which enable continuous tumor proliferation. High TRF1 protein activity has been found in glioblastoma stem cells. TRF1 helps telomeres perform their functions and also plays an important role in the self-renewal of glioblastoma stem cells.

Based on all this information, researchers investigated whether inhibiting TRF1 protein activity affected the growth of glioblastoma tumors.

According to the Study Findings;

  • In laboratory animal models, inhibiting TRF1 activity reduced tumor growth and increased survival by up to 80 percent.
  • No treatment-related side effects were observed in animal models.

What Does This Study Mean for Us?

  • Telomerase activity is very high in cancer stem cells. Treatments targeting the telomerase enzyme or telomere mechanisms may therefore effectively eliminate cancer stem cells.
  • An effective treatment strategy against difficult-to-treat tumors such as glioblastoma has thus been discovered.
  • It is important to emphasize that this work is still being tested in the laboratory. Further studies are required to demonstrate its validity and effectiveness.

It should also be noted that various products have been sold in recent years promising longevity and claiming to lengthen telomeres by increasing telomerase activity. These are marketed as supplements, not medicines. Telomerase is most active in cancer cells. Cancer cells have developed mechanisms preventing their telomeres from shortening. We must therefore state that taking supplements to lengthen our telomeres is, in our view, highly risky in terms of cancer. The most natural and appropriate way to protect telomeres is through healthy lifestyle habits, proper nutrition and regular exercise.

Sources

Leire Bejarano, Alberto J. Schuhmacher, Marinela Méndez ve ark.
Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.
Cancer Cell, November 2017
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Target for Treating the Aggressive Brain Tumor Gliobastoma: Telomere Proteins!

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy